PHARMAS CRUSHED BY THE NOVO SPELL
02/01/25 -"Pharmas closed the year with a dreadful performance, itself the reflection of dashed excessive hopes for GLP-1 developments. The unwarranted Novo Nordisk collapse on 19-12 on a marginal miss in its ..."
Pages
60
Language
English
Published on
02/01/25
You may also be interested by these reports :
21/01/25
We have reduced our NAV valuation, particularly for the seabed leases, following the DKK 3.5bn impairment write-down and the executive order issued ...
21/01/25
Ørsted announced a new impairment wave totalling DKK 12.1bn (€1.62bn), a blow to the company as it sought to regain market confidence partly through ...
17/01/25
Catherine MacGregor, CEO, announced a reorganisation of the Group’s Global Business Units (GBUs) starting in 2025. Known for frequent changes, such ...
02/01/25
EDP (Buy; Portugal) is an integrated power player which, alongside its power and gas supply business, benefits from a diverse range of assets. ...